TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Fusion Pharm Inc (OTCMKTS:FSPM) Investor Securities Class Action Lawsuit 02/17/2017

  • If you purchased shares of Fusion Pharm Inc (OTCMKTS:FSPM), you may have certain options. Please contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this case, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Lawsuit Overview

Company
Fusion Pharm Inc
Security
OTCMKTS: FSPM

Case Name
Fusion Pharm Shareholder Class Action Lawsuit 02/17/2017
Type of Lawsuit
Shareholder Class Action
Court of Filing
U.S. District Court for the District of Colorado

Class Period Begin
Class Period End
Deadline To File for Lead
You must register or login to receive notifications.

Click here to subscribe to Fusion Pharm Inc.
Summary

February 17, 2017 (Shareholders Foundation) - An investor in shares of Fusion Pharm Inc (OTCMKTS:FSPM) filed a lawsuit in the U.S. District Court for the District of Colorado over alleged violations of Federal Securities Laws by Fusion Pharm Inc in connection with certain allegedly false and misleading statements made between March 31, 2012 and September 16, 2016.

According to the complaint the plaintiff alleges on behalf of purchasers of FusionPharm Inc (OTCMKTS:FSPM) common shares between March 31, 2012 and September 16, 2016, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between March 31, 2012 and September 16, 2016, the defendants caused the Company to issue materially misleading representations and/or omit material information regarding the Company's purported revenues and sales of its PharmPods during the Class Period On September 16, 2016, the Securities and Exchange Commission (“SEC”) announced fraud charges against Fusion Pharm Inc and its CEO, Scott M. Dittman, among others, for allegedly misleading investors by recording and trumpeting revenues for purported sales of PharmPods by round-tripping money from illegal stock sales by hidden affiliates.